Aspire Biopharma Holdings Inc ASBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
-
Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
-
Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)
-
Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs
-
Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
-
Aspire Biopharma Issues Shareholder Letter
-
Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members
Trading Information
- Previous Close Price
- $7.11
- Day Range
- $7.14–7.90
- 52-Week Range
- $3.31–1,050.36
- Bid/Ask
- $7.50 / $7.78
- Shares Outstanding
- 1.30M
- Market Cap
- $10.17M
- Volume/Avg
- 34,757 / 384,840
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.aspirebiolabs.com
Valuation
|
Metric
|
ASBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.34 |
Price/Sales | 11.32 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASBP
|
|---|---|
Quick Ratio | 1.86 |
Current Ratio | 2.26 |
Interest Coverage | −0.20 |
Quick Ratio
ASBP
Profitability
|
Metric
|
ASBP
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ASBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|NDn%DNS | LOCK|#?Mcd | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|KbttyWq | LOCK|VLr@T | $83B | |||
| argenx SE ADR
ARGX
| LOCK|?^g!$>f | LOCK|qM? | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^@bn^K!# | LOCK|NKZ@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|BHWVs# | LOCK|&P | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?rlt%bQ | LOCK|B<^! | $31B | |||
| Moderna Inc
MRNA
| LOCK|k#b$>!$ | LOCK|&C | $25B | |||
| Incyte Corp
INCY
| LOCK|&T@@<r | LOCK|#j^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|c&#&&wh | LOCK|$>S | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|hB&QYvM | LOCK|vG | $16B |
United States